BRISTOL-MYERS Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
The US initial public offering (IPO) market is in the early innings of a recovery on hopes of potential interest-rate cuts and lower market volatility.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.
Already have an account? Log in here